# Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

> **NCT02839720** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Cutaneous Neurofibroma
- Neurofibromatosis Type 1
- Optic Nerve Glioma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Selumetinib Sulfate

## Key facts

- **NCT ID:** NCT02839720
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-26
- **Primary completion:** 2022-11-05
- **Final completion:** 2023-08-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02839720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02839720, "Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02839720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*